Research Analysts Issue Forecasts for Evolent Health Inc’s Q4 2018 Earnings (EVH)
Evolent Health Inc (NYSE:EVH) – Stock analysts at KeyCorp issued their Q4 2018 earnings per share (EPS) estimates for shares of Evolent Health in a research report issued on Wednesday. KeyCorp analyst D. Hooker forecasts that the technology company will post earnings of ($0.01) per share for the quarter. KeyCorp currently has a “Overweight” rating and a $23.00 price target on the stock.
Evolent Health (NYSE:EVH) last issued its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.08) by $0.04. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The firm had revenue of $107.90 million during the quarter, compared to analyst estimates of $104.49 million. During the same period last year, the company earned ($0.26) EPS. Evolent Health’s quarterly revenue was up 79.2% compared to the same quarter last year.
Evolent Health (NYSE EVH) opened at $15.05 on Friday. Evolent Health has a fifty-two week low of $10.30 and a fifty-two week high of $27.50. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.11.
Several large investors have recently made changes to their positions in EVH. FMR LLC increased its holdings in shares of Evolent Health by 117.7% in the 2nd quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock valued at $250,073,000 after acquiring an additional 5,333,252 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Evolent Health by 37.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,465,019 shares of the technology company’s stock valued at $136,236,000 after acquiring an additional 2,026,893 shares during the period. Vanguard Group Inc. increased its holdings in shares of Evolent Health by 48.9% in the 2nd quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock valued at $95,566,000 after acquiring an additional 1,237,941 shares during the period. Kornitzer Capital Management Inc. KS purchased a new position in shares of Evolent Health in the 3rd quarter valued at $14,258,000. Finally, Jennison Associates LLC purchased a new position in shares of Evolent Health in the 3rd quarter valued at $12,531,000. Institutional investors and hedge funds own 95.38% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was stolen and republished in violation of United States and international trademark and copyright law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2018/01/14/research-analysts-issue-forecasts-for-evolent-health-incs-q4-2018-earnings-evh.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Stock Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related stocks with our FREE daily email newsletter.